Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV000772898 | SCV000906280 | pathogenic | Hereditary cancer-predisposing syndrome | 2018-05-21 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001388158 | SCV001589029 | pathogenic | Familial cancer of breast | 2022-09-07 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 628431). This variant has not been reported in the literature in individuals affected with PALB2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Glu956*) in the PALB2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PALB2 are known to be pathogenic (PMID: 17200668, 17200671, 17200672, 24136930, 25099575). |
Myriad Genetics, |
RCV001388158 | SCV004189490 | pathogenic | Familial cancer of breast | 2023-09-14 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |
Baylor Genetics | RCV001388158 | SCV004202743 | likely pathogenic | Familial cancer of breast | 2022-04-21 | criteria provided, single submitter | clinical testing |